Clinical Evaluation and Local Trials in Myanmar

1. Key takeaways

Myanmar generally does not require local clinical trials for overseas medical devices. The authorities accept clinical data generated in other countries as part of the dossier, provided that the clinical studies were conducted in accordance with Good Clinical Practice (GCP) and that the study population is relevant. Together these two conditions define what makes foreign clinical data usable in Myanmar, and they should shape which studies a company selects as its evidence base.

GRZAN notes two points. First, this is a practical estimate rather than an explicit legal provision, and in individual case review the authorities may still request additional data. The correct planning posture is therefore to assume data requests are possible, not that they are impossible. Second, the requirement that the study population be relevant is a substantive standard: when citing overseas data, companies should prepare an applicability justification explaining why the data can be extrapolated to the Myanmar context of use. The applicability justification is not a formality: it is the document the reviewer reaches for whenever the data origin and the destination market diverge, and a well-argued one has repeatedly been the difference between acceptance and another round of questions.

2. Legal basis

3. Expert insights

Insight 1: the absence of a local clinical trial requirement does not mean the absence of clinical evidence requirements. Class C and Class D products must still submit clinical evaluation or equivalence arguments. What is waived is the trial location, not the evidence requirement, and companies that conflate the two underestimate the dossier work for higher-class devices. The evidence obligation follows the risk class, while the location flexibility follows the authority’s acceptance of foreign data; the two operate independently.

Insight 2: the relevance of the study population is a substantive standard that can be challenged. If the subjects of the overseas clinical data differ significantly from the Myanmar target population in disease spectrum, physiology or healthcare conditions, the authorities may request supplementary argumentation. Companies should proactively prepare an ethnic sensitivity or applicability analysis rather than waiting for the question to arrive in a deficiency letter. Addressing the issue first also signals to the reviewer that the company understands the limits of its own data.

Insight 3: the equivalence route is particularly important for Class B products. Class B is determined case by case, and a company that can cite an equivalent device already approved in another ASEAN market can markedly improve its approval prospects. Building the equivalence argument on regional precedents also shortens the reviewer’s verification path, because the referenced approvals are already familiar to the authority.

Insight 4: international certifications support the argument but do not constitute automatic recognition. Holding the CE mark or a US FDA approval can support the justification, but it cannot replace the local application to the Myanmar FDA. The certificates travel with the dossier; they do not travel instead of it, and no provision anywhere in the system exempts a CE-marked device from the local process.

Insight 5: review intensity is higher for high-risk products. The design and clinical evidence of Class C and Class D products is examined more strictly, and companies must reserve time for multiple rounds of deficiency responses rather than planning around the ideal timeline. Each additional round is a full cycle of reviewer questions, AR handling and manufacturer responses, so the calendar should absorb at least one contingency round for high-risk submissions.

4. Practical recommendations

• Determine whether clinical evaluation is needed according to the class. Class A is usually exempt, Class B is case by case, and Class C / D require it.
• Prepare an applicability justification for overseas clinical data. Explain the relevance of the study population explicitly, covering disease spectrum, care setting and any demographic differences that the reviewer is likely to probe.
• Cite approvals of equivalent devices in other ASEAN markets as supporting material. Attach them to the equivalence argument, with the approval numbers and scope statements clearly identified so the reviewer can verify them without additional enquiries.
• Reserve time for multiple rounds of deficiency responses for Class C / D products. Do not schedule production against the ideal timeline, because clinical questions are the most expensive category of deficiency to answer late.
• Do not treat international certifications as a basis for skipping the submission. The Myanmar local application must still be completed.

5. Verification checklist

• □ It has been confirmed that Myanmar generally does not require local clinical trials (practical estimate)
• □ The need for clinical evaluation has been determined according to the class
• □ It has been confirmed that the overseas clinical data complies with GCP
• □ A justification of the relevance of the study population has been prepared
• □ Approvals of equivalent devices in other markets have been collected as supporting material
• □ Time for deficiency responses has been reserved for high-risk products
• □ It has been confirmed that international certifications do not waive the local submission obligation

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com